This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical siteSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Click here for VELSIPITY▼ (etrasimod) Prescribing Information. Adverse event reporting can be found at the bottom of the page.

 Home

Menu

Close

Unmet NeedEfficacyEfficacy Home PageTrial DesignClinical RemissionEndoscopic ImprovementCorticosteroid-Free RemissionIsolated ProctitisBio/JAKi Subgroups DataInduction RespondersSymptomatic ResponseBowel UrgencySafetyAdverse eventsPooled and Interim Safety DataSpecial Warnings and PrecautionsCardiac and Ocular Adverse ReactionsGetting StartedGetting StartedContraindications and Interactions

Pre-first Dose TestingResourcesEventsMaterialsVideos

VELSIPITY is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.1
Patients with UC may feel hesitant when switching to advanced therapy3,5Conventional therapies include 5-ASA, corticosteroids and thiopurines. Advanced therapies include biologics, JAKis and S1P receptor modulators2

Disease burden

~50% of patients with UC receiving conventional therapy may be experiencing an unnecessary, disruptive disease burden2

  • Steroid use increases risk of infections and long-term exposure (>6 months) is associated with corticosteroid-related side effects, including:4
    - Adrenal suppression

    - Osteoporosis

    - Diabetes

    - Cardiovascular events

    - Mood disorders

    - All-cause mortality
Loading

Patient hesitation

The most common reasons eligible patients feel hesitant about receiving advanced therapy include:5

  • Worries about infection risks              
  • Fear of adverse events                   
  • Concerns about injections or infusions
Loading

Isolated proctitis

~1 out of 3 patients with UC are living with isolated proctitis, which can cause distressing symptoms like urgency and rectal bleeding3,6-8

    Loading     An oral treatment that may help UC patients calm their UC symptoms1,2,9 See VELSIPITY's efficacy data

    Explore trial data and efficacy outcomes such as clinical remission, endoscopic improvement and corticosteroid-free remission.

     EFFICACY DATALoading    5-ASA – aminosalicylate; JAKi – janus kinase inhibitor; S1P – sphingosine-1-phosphate; UC – ulcerative colitis.ReferencesVELSIPITY Summary of Product Characteristics.Peyrin-Biroulet L et al. Dig Liver Dis 2016;48(6):601-607.Cohen RD and Weisshof R. Gastroenterol Hepatol (NY) 2020;16(1):21-27.Blackwell J et al. Frontline Gastroenterol 2020;12(3):207-213. Afzali A et al. Adv Ther 2023;40(10):4321-4338. D'Haens GRAM et al. Drugs R D 2019;19(2):227-234.da Costa Ferreira S et al. Turk J Gastroenterol 2020;33(4):320-328.Kyriacou M et al. BMJ Open Gastroenterol 2023;10(1):1-7.Danese S et al. Dig Dis 2019;37(4):266-283.
    PP-V1A-GBR-0019. August 2024

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

    for MHRA Yellow Card in Google Play or Apple App Store

     

    Adverse events should also be reported to Pfizer Medical Information on 01304 616161

    PfizerPro Account

    To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

    Sign In or RegisterAccountSign Out

    This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

     

    This website is brought to you by Pfizer Limited, a company registered in England 

    and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

     

    Copyright © 2024 Pfizer Limited. All rights reserved.

     

    VAT registration number GB201048427

    PP-UNP-GBR-7866. January 2024
    You are now leaving PfizerPro​​​​​
    ​
    You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

    Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

    ​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
    ​​​​​​​
    For UK Healthcare Professionals*

    These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

    I confirm that I am a healthcare professional* resident in the United Kingdom.

    If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

    *The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

    PP-UNP-GBR-7812. January 2024

    YesNo
    You are now leaving PfizerPro
    ​​​​​​​
    ​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

    Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
    business which it has provided or reviewed.

    PP-PFE-GBR-3859. November 2021
    ​​​​​​​